[1] Ribes, Antonia, Pajares,et al. Neonatal Screening for Inherited Metabolic Diseases in 2016s. Seminars in Pediatric Neurology, 2016. <DOI: 10.1016/j.spen.2016.11.001>
[2] Gu xuefan. Clinical genetic metabolic diseases. Beijing: People's Health Publishing House, 2015.80-84 <ISBN: 9787117207287>
[3] Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003; 49:1797–817. <DOI: 10.1373/clinchem.2003.022178>
[4] Zhao Z Y. Progress of neonatal genetic metabolic disease screening. Chinese Journal of Practical Pediatrics, 2014, 29 (8): 586-589<DOI: 10.7504/ek2014080607>
[5] Khneisser, I., Adib, S., Assaad, S., Megarbane, A., & Karam, P. Cost-benefit analysis: Newborn screening for inborn errors of metabolism in Lebanon. Journal of Medical Screening, 22(4), 182–186. <DOI: 10.1177/0969141315590675>
[6] Zhejiang Provincial Bureau of Statistics [homepage on the Internet]. Statistical data; Statistical Yearbook [updated 2019 Sep.; cited 2020 Aug 6].2019 Zhejiang statistical yearbook. Available from: http://tjj.zj.gov.cn/col/col1525563/index.html
[7] The State Council, The People's Republic of China [homepage on the Internet]. News; Administrative News Broadcast; News Section [updated 2017 Jul 28; cited 2020 Aug 6]. Special education promotion planⅡ(2017—2020).Available from: http://www.gov.cn/xinwen/2017-07/28/content_5214071.htm
[8] Jiaxing Disabled Person's Federation [homepage on the Internet]. Information; Rehabilitation Services [updated 2017 Nov 15; cited 2020 Aug 6]. Measures for the implementation of basic rehabilitation services and subsidy system for disabled children in Zhejiang Province. Available from: http://www.jxdpf.org.cn/news/show.php?itemid=12228
[9] Chen Y Y. Economic evaluation of disease burden and prevention strategies of birth defects in China. Fudan University Press, 2007. <ISBN:9787309053265>
[10] Chiu M Y L, Yang X, Wong H T, et al. The mediating effect of affective stigma between face concern and general mental health – The case of Chinese caregivers of children with intellectual disability. Res Dev Disabil, 2015, 36:437-446.<DOI:10.1016/j.ridd.2014.10.024>
[11] Lin J D, Hu J, Yen C F, et al. Quality of life in caregivers of children and adolescents with intellectual disabilities: Use of WHOQOL-BREF survey. Research in Developmental Disabilities, 2009, 30(6):1448-1458. <DOI: 10.1016/j.ridd.2009.07.005>
[12] Starrett, DavidA. Foundations of public economics. Cambridge University Press, 1988. <DOI:10.1111/j.1475-4932.1935.tb02774.x>
[13] Lipscomb, Joseph & Weinstein, M.C. & Torrance, George. (1996). Time preference. Cost-Effectiveness in Health and Medicine. 214-235. <DOI: 10.4324/9781315623375-55>
[14] Liu G E, Hu S L, et al. Chinese guide for Pharmacoeconomic Evaluations, 2020 edition. China Market Press, 2020. <ISBN:9787509219171>
[15] Sergei Korenev, Hugh Lemonde, Maureen Cleary, Anupam Chakrapani. Newborn screening for inborn errors of metabolism. Paediatrics & Child Health, 2015, 25(3):103-107. <DOI:10.1016/j.paed.2014.10.010>
[16] E. Simon, M. Schwarz, J. Roos, N. Dragano, M. Geraedts, J. Siegrist, et al.Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual. Life Outcomes, 6 ,2008, pp. 6-25 <DOI: 10.1186/1477-7525-6-25>
[17] M. Bik-Multanowski, B. Didycz, R. Mozrzymas, M. Nowacka, L. Kaluzny, W. Cichy, B. Schneiberg, et al. Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. J. Inherit. Metab. Dis., 31 (Suppl 2),2008 pp. 415-418 <DOI:10.1007/s10545-008-0978-7>
[18] R Gassió, Campistol J , Vilaseca M A , et al. Do adult patients with phenylketonuria improve their quality of life after introduction/resumption of a phenylalanine-restricted diet?Acta aediatrica,2010,92(12):1474-1478.<DOI:10.1111/j.1651-2227.2003.tb00834.x>
[19] Bosch A M , Tybout W , Spronsen F J V , et al. The course of life and quality of life of early and continuously treated Dutch patients with phenylketonuria. Journal of Inherited Metabolic Disease, 2007, 30(1):29.<DOI:10.1007/s10545-006-0433-6>
[20] Nicolaides P, Leonard J, Surtees R. Neurological outcome of methylmalonic acidaemia. Arch Dis Child 1998;78:508–12. <DOI: 10.1136/adc.78.6.508>
[21] Lauren E.Cipriano, C. AnthonyRupar, Gregory S.Zaric. The Cost-Effectiveness of Expanding Newborn Screening for up to 21 Inherited Metabolic Disorders Using Tandem Mass Spectrometry: Results from a Decision-Analytic Model. Value in Health, 2010, 10(2):83-97. <DOI: 10.1111/j.1524-4733.2006.00156.x>
[22] Rousson R, Guibaud P. Long term outcome of organic acidurias: survey of 105 French cases (1967– 83). J Inherit Metab Dis 1984;7(Suppl. 1):10–2. <DOI: 10.1007/BF03047366>
[23] Pollitt RJ, Green A, McCabe CJ, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1997;1:1–202
[24] Bjugstad KB, Goodman SI, Freed CR. Age at symptom onset predicts severity of motor impairment and clinical outcome of glutaric acidemia type 1. J Pediatr 2000;137:681–6.< DOI:10.1067/mpd.2000.108954>
[25] Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003;49:1797–817.< DOI: 10.1373/clinchem.2003.022178>
[26] Vianey-Saban C, Divry P, Brivet M, et al. Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase defficiency: clinical characteristics and diagnostic considerations in 30 patients. Clin Chim Acta 1998;269:43–62.< DOI: 10.1016/S0009-8981(97)00185-X>
[27] Flemming Skovbya, Mette Gaustadnesb, S. Harvey Mudd et al. A revisit to the natural history of homocystinuria due to cystathionine β-synthase deficiency. Molecular Genetics and Metabolism.2010;99(1):1-3.<DOI:10.1016/j.ymgme.2009.09.009>
[28] Sweetman L, Williams J. Chapter 93: Branched chain organic acidurias. In: Scriver CR, ed., The Metabolic and Molecular Bases of Inherited Disease (8th ed.). New York: McGraw-Hill, 2001. < DOI:10.1023/A:1017409002434>
[29] Pandor A, Eastham J, Beverley C, et al. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess 2004;8:1–121.
[30] Hui J, Tang N L S , Li C K , et al. Inherited metabolic diseases in the Southern Chinese population: spectrum of diseases and estimated incidence from recurrent mutations. Pathology, 2015, 46(5):375. < DOI:10.1097/PAT.0000000000000140>
[31] Applegarth, D. A., Toone, J. R., and Lowry, R. B. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics, 2000(105): e10. < DOI:10.1542/peds.105.1.e10>
[32] Lindner, M., Gramer, G., Haege, G., Fang-Hoffmann, J., Schwab, K. O., Tacke, U., et al. Efficacy and outcome of expanded newborn screening for metabolic diseases–report of 10 years from South-West Germany. Orphanet J. RareDis. 2011(6):44. <DOI:10.1186/1750-1172-6-44>
[33] Hassan, F. A., El-Mougy, F., Sharaf, S. A., Mandour, I., Morgan, M. F., Selim, L. A., et al. Inborn errors of metabolism detectable by tandem mass spectrometry in Egypt: the first newborn screening pilot study. J. Med. Screen. 2016(23):124-129. <DOI:10.1177/0969141315618229>
[34] Yunus, Z. M., Rahman, S. A., Choy, Y. S., Keng, W. T., and Ngu, L. H. Pilot study of newborn screening of inborn error of metabolism using tandem mass spectrometry in Malaysia: outcome and challenges. J. Pediatr. Endocrinol. Metab. 2016.(29):1031–1039. <DOI:10.1515/jpem-2016-0028>
[35] Yoon, H. R., Lee, K. R., Kang, S., Lee, D. H., Yoo, H. W., Min, W. K., et al. Screening of newborns and high-risk group of children for inborn metabolic disorders using tandem mass spectrometry in South Korea: a three-year report. Clin. Chim. Acta.2004(354): 167–180. <DOI: 10.1016/j.cccn.2004. 11.032>
[36] Lim, J. S., Tan, E. S., John, C. M., Poh, S., Yeo, S. J., Ang, J. S., et al. Inborn Error of Metabolism (IEM) screening in Singapore by electrospray ionization-tandem mass spectrometry(ESI/MS/MS):an 8 year journey from pilot to current program. Mol.Genet.Metab. 2014(113):53–61.<DOI:10.1016/j.ymgme. 2014.07.018>
[37] Niu DM, Chien YH, Chiang CC, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. J Inherit Metab Dis 2010; 33: S295–305. <DOI:10.1007/s10545-010-9129-z>
[38] Lin Y , Zheng Q , Zheng T , et al. Expanded newborn screening for inherited metabolic disorders and genetic characteristics in a southern Chinese population. Clinica Chimica Acta, 2019, 494:106-111. < DOI:10.1016/j.cca.2019.03.1622>
[39] Shi XT. et al. Newborn Screening for Inborn Errors of Metabolism in Mainland China: 30 Years of Experience. JIMD Reports, 2012/3.vol 6. Springer, Berlin, Heidelberg. <DOI:10.1007/8904_2011_119>
[40] Zhu, F., Xu, J., Dong, L., and Mou, K. Analysis of 25243 cases of neonatal genetic metabolic disease screening by tandem mass spectrometry. J.Binzhou Med.Univ,2015.38,300–302.
[41] Lu, H., Zheng, J., Yao, Y., Yang, M., Yao, S., Shi, N., et al. (2016). A retrospective analysis of tandem mass spectrometry screening for neonatal genetic metabolic diseases in Yancheng area. J. Birth Health Hered.24,83–85 < DOI: 10.13404/j.cnki.cjbhh.2016.03.036>
[42] Lin Y, Huang X C, Wen W, Chen W Q, Zhao L L. Cost benefit analysis of neonatal disease screening in Shenzhen. Chinese Journal of social medicine, 2012,29 (03): 214-216. <DOI: 10.3969/j.issn.1673-5625.2012.03.026>
[43] Xia X H. Cost benefit analysis of neonatal disease screening in Lianyungang City. Maternal and child health care in China, V.28 (03): 395-397. <DOI: 10.7620/zgfybj.j.issn.1001-4411.2013.28.04>
[44] Man X W, Zhang Z X, Gu X F, et al. Cost benefit analysis of neonatal disease screening. China health economy, 2011, 30 (005): 91-93. <DOI: 10.3969/j.issn.1003-0743.2011.05.034>
[45] Zhang W Y, Wan L X, Zhao S H, et al. Cost benefit analysis of neonatal congenital hypothyroidism screening in Jilin Province [J]. Chinese Journal of Control of Endemic Diseases, 2013,28 (6): 443-444 <DOI: CNKI:SUN:DYBF.0.2013-03-034 >
[46] Hsu, Ching-Fen & Kang, Kun-Tai & Lee, Yungling & Chie, Wei-Chu. Cost-Effectiveness of Expanded Newborn Screening in Texas. Value in Health. 2013 16. 1103-1104. 10.1016/j.jval.2013.06.019.< DOI:10.1016/j.jval.2012.02.007>
[47] Schoen, Edgar & Baker, John & Colby, Chris. Cost-Benefit Analysis of Universal Tandem Mass Spectrometry for Newborn Screening. Pediatrics. 2002, 110. 781-6. <DOI: 10.1542/peds.110.4.781.>
[48] Lauren E.Cipriano, C. AnthonyRupar, Gregory S.Zaric. The Cost-Effectiveness of Expanding Newborn Screening for up to 21 Inherited Metabolic Disorders Using Tandem Mass Spectrometry: Results from a Decision-Analytic Model. Value in Health, 2010, 10(2):83-97. <DOI: 10.1111/j.1524-4733.2006.00156.x>
[49] Huang XW, Yang L, Tong F, et al. Screening for inborn errors of metabolism in high-risk children: a 3-year pilot study in Zhejiang Province, China. Bmc Pediatrics, 2012, 12(1):18. <DOI: 10.1186/1471-2431-12-18>
[50] Sergei Korenev, Hugh Lemonde, Maureen Cleary, et al. Newborn screening for inborn errors of metabolism, Paediatrics and Child Health, 2019, 29(3): 105-110.<DOI: 10.1016/j.paed.2019.01.002>